A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy

  • Authors:
    • Yukio Tokumitsu
    • Kazuhiko Sakamoto
    • Yoshihiro Tokuhisa
    • Hiroto Matsui
    • Satoshi Matsukuma
    • Yoshinari Maeda
    • Koichiro Sakata
    • Hiroshi Wada
    • Hidetoshi Eguchi
    • Hiroyuki Ogihara
    • Yusuke Fujita
    • Yoshihiko Hamamoto
    • Norio Iizuka
    • Tomio Ueno
    • Hiroaki Nagano
  • View Affiliations

  • Published online on: January 19, 2018     https://doi.org/10.3892/ol.2018.7821
  • Pages: 4411-4422
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

We previously reported the effectiveness of the product of tumor number and size (NxS factor) for the prognosis of hepatocellular carcinoma (HCC) in patients following hepatectomy. The present study aimed to propose a new score based on the NxS factor to predict HCC recurrence following hepatectomy. A total of 406 patients who underwent hepatectomy for HCC at Osaka University Graduate School of Medicine were retrospectively analyzed to develop the new score. Among clinicopathological factors, including the NxS factor, the marker subset that achieved the best performance for prediction of early recurrence was assessed, and a prognostic model for HCC recurrence after curative hepatectomy (REACH) was developed. As the validation set, 425 patients who underwent hepatectomy for HCC at Yamaguchi University Graduate School of Medicine and Shimonoseki Medical Center were analyzed, and the prognostic ability of the REACH score was compared with that of well‑known staging systems. Following analysis, the REACH score was constructed using six covariates (NxS factor, microscopic hepatic vein invasion, differentiation, serum albumin, platelet count and indocyanine green retention rate at 15 min). In the validation set, the REACH score predicted early recurrence in 73 of 81 samples, with a sensitivity of 89% and a specificity of 58%. The area under the curve (AUC) of the receiver operating characteristic curve of the REACH score was 0.78 and 0.74, respectively, for 1‑ and 2‑year recurrence after hepatectomy; each AUC was higher than that of any of the other staging systems. Survival analysis indicated the REACH score had the best predictive value in disease‑free and overall survival. The present findings demonstrated that the REACH score may be used to classify patients with HCC into high‑ and low‑risk of recurrence, and to predict subsequent survival following hepatic resection.

References

1 

Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G and Gramlich T: AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: Consensus statement. HPB (Oxford). 5:243–250. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR II, et al: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 465:96–100. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Kudo M, Chung H and Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol. 38:207–215. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y and Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology. 40:1396–1405. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Nanashima A, Sumida Y, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Ide N, Sawai T, Yasutake T, Nakagoe T and Nagayasu T: The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 30:765–770. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, Hidaka S, Tanaka K, Sawai T, Yasutake T, et al: Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol. 41:250–256. 2006. View Article : Google Scholar : PubMed/NCBI

10 

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The cancer of the liver Italian program (CLIP) investigators. Hepatology. 28:751–755. 1998. View Article : Google Scholar : PubMed/NCBI

11 

Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 31:840–845. 2000. View Article : Google Scholar : PubMed/NCBI

12 

Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, et al: Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 54:419–425. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Llovet JM, Brú C and Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI

14 

Llovet JM, Fuster J and Bruix J: The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 10 2 Suppl 1:S115–S120. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Poon RT, Fan ST, Ng IO, Lo CM, Liu CL and Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 89:500–507. 2000. View Article : Google Scholar : PubMed/NCBI

16 

Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M and Sata M: Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 15:1375–1382. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Kim H, Park MS, Park YN, Kim H, Kim KS, Choi JS, Ahn SH, Han KH, Kim MJ and Kim KW: Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection. Yonsei Med J. 50:789–795. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Park YK, Kim BW, Wang HJ and Kim MW: Hepatic resection for hepatocellular carcinoma meeting Milan criteria in Child-Turcotte-Pugh class a patients with cirrhosis. Transplant Proc. 41:pp. 1691–1697. 2009; View Article : Google Scholar : PubMed/NCBI

19 

Fan ST, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, Ng KK, Liu CL and Chan SC: Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg. 98:1292–1300. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Tokumitsu Y, Tamesa T, Matsukuma S, Hashimoto N, Maeda Y, Tokuhisa Y, Sakamoto K, Ueno T, Hazama S, Ogihara H, et al: An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol. 46:944–952. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Tokumitsu Y and Nagano H: Current HCC Staging Systems: Their Uses and LimitationsHepatocellular Carcinoma: Diagnosis and Treatment. Carr BI: Springer; Switzerland: pp. 425–442. 2016, View Article : Google Scholar

22 

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI

23 

The general rules for the clinical and pathological study of primary liver cancer. Kanehara; Tokyo: 2010

24 

Clinical Practice Guidelines for Hepatocellular Carcinoma-The Japan Society of Hepatology 2009 update. Hepatol Res. 1 40 Suppl:S2–S144. 2010.

25 

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI

26 

Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y and Makuuchi M: Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 245:909–922. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Cho CS, Gonen M, Shia J, Kattan MW, Klimstra DS, Jarnagin WR, D'Angelica MI, Blumgart LH and DeMatteo RP: A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg. 206:281–291. 2008. View Article : Google Scholar : PubMed/NCBI

28 

Li J, Liu Y, Yan Z, Wan X, Xia Y, Wang K, Liu J, Lau WY, Wu M and Shen F: A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy. Br J Cancer. 110:1110–1117. 2014. View Article : Google Scholar : PubMed/NCBI

29 

Zou Q, Li J, Wu D, Yan Z, Wan X, Wang K, Shi L, Lau WY, Wu M and Shen F: Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg Oncol. 23:2618–2626. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, et al: The Singapore Liver Cancer Recurrence (SLICER) score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 10:e01280582015. View Article : Google Scholar : PubMed/NCBI

31 

Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, Yagi S and Uemoto S: Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection. Surgery. 151:55–60. 2012. View Article : Google Scholar : PubMed/NCBI

32 

Iizuka N, Hamamoto Y and Oka M: Predicting individual outcomes in hepatocellular carcinoma. Lancet. 364:1837–1839. 2004. View Article : Google Scholar : PubMed/NCBI

33 

Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, et al: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 361:923–929. 2003. View Article : Google Scholar : PubMed/NCBI

34 

Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, Umeshita K, Sakon M, Ueno N, Oba S, et al: Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 41:284–291. 2004. View Article : Google Scholar : PubMed/NCBI

35 

Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, Luk JM and Salto-Tellez M: A morpho-molecular prognostic model for hepatocellular carcinoma. Br J Cancer. 107:334–339. 2012. View Article : Google Scholar : PubMed/NCBI

36 

Yoshioka S, Takemasa I, Nagano H, Kittaka N, Noda T, Wada H, Kobayashi S, Marubashi S, Takeda Y, Umeshita K, et al: Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer. 45:881–889. 2009. View Article : Google Scholar : PubMed/NCBI

37 

Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K and Tsuneyoshi M: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 108:768–775. 1995. View Article : Google Scholar : PubMed/NCBI

38 

Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G and Tsurumaru M: Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer. 71:19–25. 1993. View Article : Google Scholar : PubMed/NCBI

39 

Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, Miyamoto A, Kondo M, Arai I, Yamamoto T, et al: Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol. 39:215–221. 2003. View Article : Google Scholar : PubMed/NCBI

40 

Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, Ohshima S, Dono K, Nakamori S, Gotoh M and Monden M: Clinical significance of hepatic resection in hepatocellular carcinoma: Analysis by disease-free survival curves. Arch Surg. 135:1456–1459. 2000. View Article : Google Scholar : PubMed/NCBI

41 

Lau H, Man K, Fan ST, Yu WC, Lo CM and Wong J: Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 84:1255–1259. 1997. View Article : Google Scholar : PubMed/NCBI

42 

Wakabayashi H, Ishimura K, Izuishi K, Karasawa Y and Maeta H: Evaluation of liver function for hepatic resection for hepatocellular carcinoma in the liver with damaged parenchyma. J Surg Res. 116:248–252. 2004. View Article : Google Scholar : PubMed/NCBI

43 

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al: Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 45:123–127. 2015. View Article : Google Scholar

44 

Song P, Inagaki Y, Wang Z, Hasegawa K, Sakamoto Y, Arita J, Tang W and Kokudo N: High levels of gamma-glutamyl transferase and indocyanine green retention rate at 15 min as preoperative predictors of tumor recurrence in patients with hepatocellular carcinoma. Medicine (Baltimore). 94:e8102015. View Article : Google Scholar : PubMed/NCBI

45 

Zhao H, Chen C, Fu X, Yan X, Jia W, Mao L, Jin H and Qiu Y: Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection. Oncotarget. 8:5474–5486. 2017.PubMed/NCBI

46 

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, et al: Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J Clin Oncol. 33:550–558. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tokumitsu, Y., Sakamoto, K., Tokuhisa, Y., Matsui, H., Matsukuma, S., Maeda, Y. ... Nagano, H. (2018). A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncology Letters, 15, 4411-4422. https://doi.org/10.3892/ol.2018.7821
MLA
Tokumitsu, Y., Sakamoto, K., Tokuhisa, Y., Matsui, H., Matsukuma, S., Maeda, Y., Sakata, K., Wada, H., Eguchi, H., Ogihara, H., Fujita, Y., Hamamoto, Y., Iizuka, N., Ueno, T., Nagano, H."A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy". Oncology Letters 15.4 (2018): 4411-4422.
Chicago
Tokumitsu, Y., Sakamoto, K., Tokuhisa, Y., Matsui, H., Matsukuma, S., Maeda, Y., Sakata, K., Wada, H., Eguchi, H., Ogihara, H., Fujita, Y., Hamamoto, Y., Iizuka, N., Ueno, T., Nagano, H."A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy". Oncology Letters 15, no. 4 (2018): 4411-4422. https://doi.org/10.3892/ol.2018.7821